NO310513B1 - Farmasöytisk preparat inneholdende et peptid som aktiv bestanddel, og anvendelse av et peptid for fremstilling av etmedikament for behandling av multippel sklerose - Google Patents
Farmasöytisk preparat inneholdende et peptid som aktiv bestanddel, og anvendelse av et peptid for fremstilling av etmedikament for behandling av multippel sklerose Download PDFInfo
- Publication number
- NO310513B1 NO310513B1 NO19941415A NO941415A NO310513B1 NO 310513 B1 NO310513 B1 NO 310513B1 NO 19941415 A NO19941415 A NO 19941415A NO 941415 A NO941415 A NO 941415A NO 310513 B1 NO310513 B1 NO 310513B1
- Authority
- NO
- Norway
- Prior art keywords
- mbp
- peptide
- seq
- amino acid
- peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 100
- 201000006417 multiple sclerosis Diseases 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims description 10
- 239000003814 drug Substances 0.000 title claims description 6
- 239000004480 active ingredient Substances 0.000 title claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 4
- 229940079593 drug Drugs 0.000 title claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 58
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 27
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 8
- 101001018318 Homo sapiens Myelin basic protein Proteins 0.000 claims description 28
- 102000054064 human MBP Human genes 0.000 claims description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 230000002502 anti-myelin effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 102000006386 Myelin Proteins Human genes 0.000 abstract description 9
- 108010083674 Myelin Proteins Proteins 0.000 abstract description 9
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 238000007913 intrathecal administration Methods 0.000 abstract description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 31
- 102000047918 Myelin Basic Human genes 0.000 description 30
- 101710107068 Myelin basic protein Proteins 0.000 description 29
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 29
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 13
- 238000006386 neutralization reaction Methods 0.000 description 13
- 230000001154 acute effect Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000012071 phase Substances 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 208000016192 Demyelinating disease Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 206010012305 Demyelination Diseases 0.000 description 4
- LKDXINHHSWFFJC-SRVKXCTJSA-N Lys-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)N LKDXINHHSWFFJC-SRVKXCTJSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108010057821 leucylproline Proteins 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- JAMAWBXXKFGFGX-KZVJFYERSA-N Ala-Arg-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JAMAWBXXKFGFGX-KZVJFYERSA-N 0.000 description 3
- LBFXVAXPDOBRKU-LKTVYLICSA-N Ala-His-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LBFXVAXPDOBRKU-LKTVYLICSA-N 0.000 description 3
- DINOVZWPTMGSRF-QXEWZRGKSA-N Asp-Pro-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O DINOVZWPTMGSRF-QXEWZRGKSA-N 0.000 description 3
- DTPOVRRYXPJJAZ-FJXKBIBVSA-N Gly-Arg-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N DTPOVRRYXPJJAZ-FJXKBIBVSA-N 0.000 description 3
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 3
- APQYGMBHIVXFML-OSUNSFLBSA-N Ile-Val-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N APQYGMBHIVXFML-OSUNSFLBSA-N 0.000 description 3
- RMKGXGPQIPLTFC-KKUMJFAQSA-N Phe-Lys-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O RMKGXGPQIPLTFC-KKUMJFAQSA-N 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- ZTKGDWOUYRRAOQ-ULQDDVLXSA-N Val-His-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)N ZTKGDWOUYRRAOQ-ULQDDVLXSA-N 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 2
- JBSLJUPMTYLLFH-MELADBBJSA-N His-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC3=CN=CN3)N)C(=O)O JBSLJUPMTYLLFH-MELADBBJSA-N 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 108010077112 prolyl-proline Proteins 0.000 description 2
- 108010004914 prolylarginine Proteins 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- ZJBUILVYSXQNSW-YTWAJWBKSA-N Arg-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ZJBUILVYSXQNSW-YTWAJWBKSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- DEFGUIIUYAUEDU-ZPFDUUQYSA-N Lys-Asn-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DEFGUIIUYAUEDU-ZPFDUUQYSA-N 0.000 description 1
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 1
- 108700028031 Myelin Basic Proteins 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZSKJPKFTPQCPIH-RCWTZXSCSA-N Pro-Arg-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZSKJPKFTPQCPIH-RCWTZXSCSA-N 0.000 description 1
- SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101001018322 Sus scrofa Myelin basic protein Proteins 0.000 description 1
- AZGZDDNKFFUDEH-QWRGUYRKSA-N Tyr-Gly-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AZGZDDNKFFUDEH-QWRGUYRKSA-N 0.000 description 1
- DVLWZWNAQUBZBC-ZNSHCXBVSA-N Val-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N)O DVLWZWNAQUBZBC-ZNSHCXBVSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012072 active phase Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012073 inactive phase Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002761 liquid phase assay Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- RJSZPKZQGIKVAU-UXBJKDEOSA-N peptide f Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C(C)C)C(C)C)C1=CC=CC=C1 RJSZPKZQGIKVAU-UXBJKDEOSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000007694 polyacrylamide gel isoelectric focusing Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Rehabilitation Therapy (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002053799A CA2053799C (en) | 1991-10-22 | 1991-10-22 | Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid |
| PCT/CA1992/000448 WO1993008212A1 (en) | 1991-10-22 | 1992-10-15 | Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO941415D0 NO941415D0 (no) | 1994-04-19 |
| NO941415L NO941415L (de) | 1994-06-22 |
| NO310513B1 true NO310513B1 (no) | 2001-07-16 |
Family
ID=4148603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19941415A NO310513B1 (no) | 1991-10-22 | 1994-04-19 | Farmasöytisk preparat inneholdende et peptid som aktiv bestanddel, og anvendelse av et peptid for fremstilling av etmedikament for behandling av multippel sklerose |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0610446B1 (de) |
| AT (1) | ATE236193T1 (de) |
| AU (1) | AU2750092A (de) |
| CA (1) | CA2053799C (de) |
| DE (1) | DE69232987T2 (de) |
| DK (1) | DK0610446T3 (de) |
| ES (1) | ES2196007T3 (de) |
| FI (1) | FI111050B (de) |
| NO (1) | NO310513B1 (de) |
| NZ (1) | NZ244807A (de) |
| RU (1) | RU2121850C1 (de) |
| WO (1) | WO1993008212A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817629A (en) * | 1991-10-22 | 1998-10-06 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| US6252040B1 (en) * | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| EP0787147A1 (de) * | 1994-10-25 | 1997-08-06 | Immulogic Pharmaceutical Corporation | Zhusammensetzung und behandlung von multisklerose |
| CA2205532A1 (en) | 1994-11-18 | 1996-05-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein |
| US6251396B1 (en) | 1994-11-18 | 2001-06-26 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
| US6379670B1 (en) | 1994-11-18 | 2002-04-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
| US6329499B1 (en) * | 1994-11-18 | 2001-12-11 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
| WO1996028470A2 (en) * | 1995-03-09 | 1996-09-19 | Neurocrine Biosciences, Inc. | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis |
| CA2201841C (en) * | 1997-04-04 | 2010-01-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| WO2005009455A1 (fr) * | 2003-07-29 | 2005-02-03 | Terentiev Alexandr Alexandrovi | Composition de peptides presentant une propriete immunoregulatrice |
| CN102781465A (zh) | 2009-10-12 | 2012-11-14 | 生命生物实验室有限公司 | 用于治疗多发性硬化的组合物 |
| US9326773B2 (en) | 2012-01-26 | 2016-05-03 | Covidien Lp | Surgical device including buttress material |
| WO2024094562A1 (en) * | 2022-11-01 | 2024-05-10 | Universität Zürich | Novel mbp peptides and their use in the treatment of multiple sclerosis |
-
1991
- 1991-10-22 CA CA002053799A patent/CA2053799C/en not_active Expired - Lifetime
-
1992
- 1992-10-15 WO PCT/CA1992/000448 patent/WO1993008212A1/en active Search and Examination
- 1992-10-15 DE DE69232987T patent/DE69232987T2/de not_active Expired - Lifetime
- 1992-10-15 DK DK93908754T patent/DK0610446T3/da active
- 1992-10-15 RU RU94027578A patent/RU2121850C1/ru not_active IP Right Cessation
- 1992-10-15 AT AT93908754T patent/ATE236193T1/de not_active IP Right Cessation
- 1992-10-15 ES ES93908754T patent/ES2196007T3/es not_active Expired - Lifetime
- 1992-10-15 EP EP93908754A patent/EP0610446B1/de not_active Expired - Lifetime
- 1992-10-15 AU AU27500/92A patent/AU2750092A/en not_active Abandoned
- 1992-10-20 NZ NZ244807A patent/NZ244807A/xx not_active IP Right Cessation
-
1994
- 1994-04-19 NO NO19941415A patent/NO310513B1/no not_active IP Right Cessation
- 1994-04-21 FI FI941860A patent/FI111050B/fi active
Also Published As
| Publication number | Publication date |
|---|---|
| FI941860A (fi) | 1994-04-21 |
| DE69232987D1 (de) | 2003-05-08 |
| DE69232987T2 (de) | 2004-01-29 |
| ES2196007T3 (es) | 2003-12-16 |
| RU94027578A (ru) | 1996-10-20 |
| NO941415L (de) | 1994-06-22 |
| FI111050B (fi) | 2003-05-30 |
| NZ244807A (en) | 1997-08-22 |
| CA2053799A1 (en) | 1993-04-23 |
| AU2750092A (en) | 1993-05-21 |
| WO1993008212A1 (en) | 1993-04-29 |
| EP0610446A1 (de) | 1994-08-17 |
| ATE236193T1 (de) | 2003-04-15 |
| FI941860A0 (fi) | 1994-04-21 |
| CA2053799C (en) | 2002-03-12 |
| NO941415D0 (no) | 1994-04-19 |
| DK0610446T3 (da) | 2003-07-14 |
| RU2121850C1 (ru) | 1998-11-20 |
| EP0610446B1 (de) | 2003-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO310513B1 (no) | Farmasöytisk preparat inneholdende et peptid som aktiv bestanddel, og anvendelse av et peptid for fremstilling av etmedikament for behandling av multippel sklerose | |
| US6258781B1 (en) | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients | |
| US7368429B2 (en) | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients | |
| AU2005221187A1 (en) | Method for inhibiting immune complex formation in a subjetc | |
| CA2201841C (en) | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients | |
| Warren et al. | Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid | |
| Von Grünigen et al. | Antigenic structure of the hexacosapeptide melittin: evidence for three determinants, one with a helical conformation. | |
| US7090982B2 (en) | Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient | |
| JPH02504632A (ja) | 生物学的活性分子 | |
| Tsitsiloni et al. | A radioimmunoassay for parathymosin α using antibodies to synthetic N-terminal peptide 1–30 | |
| US20020111312A1 (en) | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients | |
| Defendini et al. | Identification of antigenic residues on apamin recognized by polyclonal antibodies | |
| NZ513065A (en) | Peptide fragments of MBP, their pharmaceutical compositions and their use in treating multiple sclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |